ANN ARBOR, MI--(Marketwire - May 07, 2008) - Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and autoimmune diseases, announced today that it has received a notice of allowance from the United States Patent and Trademark Office for exclusively licensed U.S. patent application Ser. No. 11/057.353 containing claims covering the use of thiomolybdates such as oral tetrathiomolybdate (oral TTM) for the treatment of Alzheimer’s disease (AD).
